Literature DB >> 10893290

Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues.

C Poremba1, C Scheel, B Hero, H Christiansen, K L Schaefer, J i Nakayama, F Berthold, H Juergens, W Boecker, B Dockhorn-Dworniczak.   

Abstract

PURPOSE: We have recently demonstrated that telomerase activity (TA) is an independent prognostic factor in neuroblastomas. In the present study, the prognostic impact of TA and gene expression of the three major telomerase subunits is evaluated by molecular and immunohistochemical techniques in fresh-frozen and paraffin-embedded tissues. PATIENTS AND METHODS: One hundred thirty-three neuroblastomas of all stages were analyzed for TA. The TA levels of 75 neuroblastoma cases were correlated with gene expression of telomerase subunits hTRT, human telomerase RNA (hTR), and telomerase protein 1 (TP1) by quantitative reverse transcriptase polymerase chain reaction (RT-PCR), using an innovative approach on the LightCycler instrument (Roche Diagnostics, Mannheim, Germany). For selected cases, the applicability of RT-PCR and immunohistochemistry for hTRT expression analysis was investigated in paraffin-embedded tissues. TA and subunit expression patterns were correlated with traditional prognostic indicators and disease outcome.
RESULTS: TA was present in a total of 39 (29.3%) of 133 neuroblastomas and in 31 (29.8%) of 104 initial neuroblastomas without cytotoxic pretreatment. TA was significantly correlated with both event-free and overall survival (P <.0001). Furthermore, we found a significant correlation between expression levels of TA and hTRT (P <.0001) as well as hTR (P <.001). Multivariate analysis revealed only TA and tumor stage but not serum lactate dehydrogenase, MYCN amplification, or age at diagnosis as independent prognostic factors.
CONCLUSION: The significant correlation with clinical outcome strongly recommends that analysis of TA be incorporated into the clinical investigation of each individual neuroblastoma at the time of diagnosis. Because the mere presence or absence of TA without further quantification is sufficient basis for predicting disease outcome, the telomeric repeat amplification protocol assay could be complemented with but not replaced by analysis of hTRT or hTR expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893290     DOI: 10.1200/JCO.2000.18.13.2582

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

1.  Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.

Authors:  Octavio Burgues; Samuel Navarro; Rosa Noguera; Antonio Pellín; Amparo Ruiz; Victoria Castel; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

2.  Nuclear telomerase is less accessible to antibody probing than known nuclear antigens: retrieval with new immunostaining buffer.

Authors:  Danny Tze-Ming Leung; Chun-Hung Ma; Haitao Niu; Choong-Tsek Liew; Janet Tsui-Ying Tang; Pak-Leong Lim
Journal:  Histochem Cell Biol       Date:  2004-11-05       Impact factor: 4.304

3.  Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma.

Authors:  Sven Lindner; Hagen S Bachmann; Andrea Odersky; Simon Schaefers; Ludger Klein-Hitpass; Barbara Hero; Matthias Fischer; Angelika Eggert; Alexander Schramm; Johannes H Schulte
Journal:  Biomed Rep       Date:  2015-05-13

4.  Sclerosing pseudovascular rhabdomyosarcoma-immunohistochemical, ultrastructural, and genetic findings indicating a distinct subtype of rhabdomyosarcoma.

Authors:  Cornelius Kuhnen; Peter Herter; Ivo Leuschner; Thomas Mentzel; Daniel Druecke; Malgorzata Jaworska; Georg Johnen
Journal:  Virchows Arch       Date:  2006-10-03       Impact factor: 4.064

5.  Curcumin regulates low-linear energy transfer γ-radiation-induced NFκB-dependent telomerase activity in human neuroblastoma cells.

Authors:  Natarajan Aravindan; Jamunarani Veeraraghavan; Rakhesh Madhusoodhanan; Terence S Herman; Mohan Natarajan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-13       Impact factor: 7.038

6.  Association of telomerase activity with radio- and chemosensitivity of neuroblastomas.

Authors:  Simone Wesbuer; Claudia Lanvers-Kaminsky; Ines Duran-Seuberth; Tobias Bölling; Karl-Ludwig Schäfer; Yvonne Braun; Normann Willich; Burkhard Greve
Journal:  Radiat Oncol       Date:  2010-07-19       Impact factor: 3.481

Review 7.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

8.  Bcl6 is expressed in neuroblastoma: tumor cell type-specific expression predicts outcome.

Authors:  Aghiad Chamdin; Jason A Jarzembowski; Chitra Subramanian; Rork Kuick; Julia Shin-Jung Lee; Roland Ps Kwok; Valerie P Castle; Anthony W Opipari
Journal:  Transl Oncol       Date:  2009-08-18       Impact factor: 4.243

9.  Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.

Authors:  Lee Ridley; Ruman Rahman; Marie-Anne Brundler; David Ellison; James Lowe; Keith Robson; Emma Prebble; Inga Luckett; Richard J Gilbertson; Sheila Parkes; Vikki Rand; Beth Coyle; Richard G Grundy
Journal:  Neuro Oncol       Date:  2008-08-13       Impact factor: 12.300

Review 10.  Senescence induction; a possible cancer therapy.

Authors:  Matilde E Lleonart; Ana Artero-Castro; Hiroshi Kondoh
Journal:  Mol Cancer       Date:  2009-01-08       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.